Cell Biotech Co., Ltd.
Financials
Valuation Metrics
Cell Biotech Co., Ltd.'s Market Cap is ₩1449B. At end of 2025 it was ₩1232B. Ranked #1043 of 2,421 in KR market (top 43%), #531 of 1,640 on KOSDAQ (top 32%), #120 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 144.85B KRW | KR#1,043/2,421 Sec#120/231 |
| Revenue | 60.40B KRW | KR#1,697/2,421 Sec#113/231 |
| Net Income | 16.80B KRW | KR#773/2,421 Sec#53/231 |
| Total Assets | 136.57B KRW | KR#1,571/2,421 Sec#122/231 |
| Net Assets | 131.64B KRW | KR#1,219/2,421 Sec#92/231 |
| Employees | 123 | KR#1,486/2,421 Sec#118/231 |
| Value | ||
| P/E | 8.62x | KR#708/2,421 Sec#32/231 |
| P/B | 1.10x | KR#1,545/2,421 Sec#100/231 |
| PEG | 0.13x | KR#467/2,421 Sec#26/231 |
| P/S | 2.40x | KR#1,896/2,421 Sec#110/231 |
| EV/EBITDA | 12.65x | KR#751/2,421 Sec#41/231 |
| FCF Yield | 5.53% | KR#816/2,421 Sec#42/231 |
| Profitability | ||
| ROE | 12.76% | KR#426/2,421 Sec#29/231 |
| ROA | 12.30% | KR#179/2,421 Sec#15/231 |
| Op. Margin | 16.72% | KR#245/2,421 Sec#23/231 |
| Revenue Growth | 27.27% | KR#420/2,421 Sec#42/231 |
| Earnings Growth | 66.14% | KR#494/2,421 Sec#33/231 |
| Financial Health | ||
| Debt Ratio | 3.75% | KR#20/2,421 Sec#8/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | 8.00B KRW | KR#775/2,421 Sec#44/231 |
| Cash | 17.14B KRW | KR#1,340/2,421 Sec#105/231 |
| Net Debt/EBITDA | -1.70x | KR#273/2,421 Sec#12/231 |
| Dividend | ||
| Div. Yield | 3.87% | KR#441/2,421 Sec#16/231 |
| Div. Growth | 33.33% | KR#328/2,421 Sec#17/231 |
| Performance | ||
| 1Y Return | 22.11% | KR#423/2,421 Sec#28/231 |
| 1M Return | 1.31% | KR#1,086/2,421 Sec#81/231 |
| From 52W High | -16.70% | KR#184/2,421 Sec#6/231 |
| 1Y MDD | -18.00% | KR#42/2,421 Sec#2/231 |
| Trading | ||
| Volume | 2,392 shares | KR#2,257/2,421 Sec#212/231 |
| Trading Value | 36.9M KRW | KR#1,941/2,421 Sec#197/231 |
| Foreign Own. | 4.22% | KR#998/2,421 Sec#90/231 |
| Per Share | ||
| EPS | 1,787 KRW | KR#485/2,421 Sec#30/231 |
| BPS | 14,004 KRW | KR#743/2,421 Sec#51/231 |
Company Info
Cell Biotech was established in 1995 for the research and manufacturing of probiotic lactic acid bacteria products and was listed on KOSDAQ in 2002. The company offers a one-stop solution from probiotic strain development to finished product manufacturing and distribution, achieving the top export position in 2023. By leveraging its dual-coating technology and launching personalized 'Cellbiom' products, Cell Biotech is expanding its business scope and product competitiveness. Cell Biotech is headquartered in Gimpo-si, Gyeonggi-do.